BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Cell Therapy
    • COVID-19
    • CAR-T
    • Cord Blood
  • Exosomes
  • Interviews
  • News
    • Press Releases
    • Job Posts
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » Interviews

BioInformant's Founder, Cade Hildreth, has interviewed hundreds of key opinion leaders (KOL's) from across the stem cell industry.

ReeLabs: Cord Blood Banking in India (Population 1.4 Billion)

March 4, 2021 By Cade Hildreth (CEO) Leave a Comment

Reelabs, cord blood banking India

ReeLabs is a leading cord blood bank in India. Cord blood banking in this region is of monumental importance, because the country has an astounding population of 1.4 billion. This represents an incredible 18% of the global population.

Meaning, one-out-of-every-five people on this planet lives in India and the country is now head-to-head with China as the world’s most populous country.

India’s population growth is fueled by a birth rate (19 births/1,000 population) that substantially exceeds its death rate (7.3 deaths/1,000 population).

If you’re involved with cord blood banking, you need to understand the important of this particular market and the trends emerging within it.

In this interview with Dr. Abhijit Bopardikar, Director of ReeLabs, he explains the rise of cord blood banking within India and discusses the importance of pairing stem cell therapy and research applications with stem cell storage services.

[Read more…]

Filed Under: Cord Blood, HSCs, Interviews, MSCs Tagged With: interview, ReeLabs

New Frontiers in Gene-Editing and Stem Cell Innovation – Interview with Dr. Chen-Tsai of Applied StemCell

January 14, 2021 By Cade Hildreth (CEO)

Applied StemCell, Inc.

Applied StemCellI had the honor of interviewing Dr. Ruby Yanru Chen-Tsai, Chief Scientific Officer and Co-founder of Applied StemCell Inc. (ASC), a fast growing biotechnology company in Milpitas, California. Specializing in gene-editing technologies and stem cell innovation, ASC offers an optimized series of tools for basic research study, drug discovery, bio-processing, bio-production and preclinical applications.

In this fascinating interview, we discuss Dr. Yanru Chen-Tsai’s impressive background, ASC’s unique product portfolio, its TARGATT™ gene editing technology, and the company’s future trajectory. [Read more…]

Filed Under: CAR-T, Interviews, Stem Cells Tagged With: Applied StemCell, gene editing, interview

Dr. Robert Hariri on Cell Therapeutics, Combination Therapies, and COVID-19

January 2, 2021 By Cade Hildreth (CEO)

Dr. Robert Hariri Celularity

With greater than 30 million cases and 946,000 deaths reported from COVID-19 worldwide, the novel Coronavirus represents one of the largest pandemics in modern history. Thankfully, it also represents the largest cooperative effort in human history.

Globally, scientists are exploring every potential weapon to suppress the threat, including vaccines, repurposed drugs, combination therapies, and as we explore here, cellular therapies with promising cell types such as natural killer (NK) cells and mesenchymal stem cells (MSCs).

In this interview with Dr. Robert Hariri, CEO of Celularity, Inc., we discuss the company’s cell therapeutics pipeline against COVID-19. Enjoy! [Read more…]

Filed Under: Cell Therapy, Coronavirus (COVID-19), Interviews

Stemmatters, a Portuguese Integrated Therapeutics Developer and Cell Therapy CDMO

January 1, 2021 By Cade Hildreth (CEO)

Stemmatters

Stemmatters is a Portuguese contract development and manufacturing (CDMO) organisation based in Barco, Guimarães. Originally a spin-off from University of Minho, it offers contract development and manufacturing services for cell-based advanced therapies, exosomes, blood-derived biologics, tissue products, biomaterials, and combination devices.

In the interview below, we explore Stemmatters history, services, manufacturing facilities, and future goals. Enjoy! [Read more…]

Filed Under: Cell Therapy, Interviews Tagged With: CDMO, interview, Stemmatters

Behind the Scenes at FUJIFILM Irvine Scientific (FISI) with Yutaka Yamaguchi (President)

December 21, 2020 By Cade Hildreth (CEO)

FUJIFILM Irvine Scientific - Product Manager Job Post

FUJIFILM Irvine Scientific (FISI) is the world’s leading manufacturer of cell culture media, reagents, and medical devices that are used across the cell therapy, regenerative medicine, assisted reproductive technology, and industrial cell culture markets. The company adheres to ISO and FDA regulations and operates dual cGMP manufacturing facilities in California, USA, and Tokyo, Japan.

While Irvine Scientific was founded in 1970, Fujifilm did not acquire the company until 2018, when it invested US$800 million to become a dominant force within the cell culture media and services market.

In this interview with Yutaka Yamaguchi, President of FUJIFILM Irvine Scientific (FISI), we explore the reasons for FUJIFILM’s acquisition of Irvine Scientific, the importance of the company’s dual manufacturing facilities, traits that differentiate FISI from its competitors, and trends within the Regenerative Medicine industry at large. [Read more…]

Filed Under: Interviews Tagged With: FUJIFILM Irvine Scientific

  • 1
  • 2
  • 3
  • …
  • 14
  • Next Page »

Let’s Get Social

  • Facebook
  • Twitter
  • Instagram
  • Pinterest
  • LinkedIn

Nanocellect

Marathon Products

Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • US Cord Blood and Cord Tissue Storage Rates Rates of U.S. Cord Blood and Cord Tissue Storage - Historical and Projected
    Rated 0 out of 5
    $197
  • Job Posting on BioInformant Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience
    Rated 0 out of 5
    $297
  • BioInformant Audience Reach BioInformant's Audience with Your Press Announcement
    Rated 0 out of 5
    $397 $297

Featured Posts

Alternate Ocean GCBC

Alternate Ocean Offers to Acquire Largest Cord Blood Bank in China (GCBC) for $5/Share

Reelabs, cord blood banking India

ReeLabs: Cord Blood Banking in India (Population 1.4 Billion)

iPSC-derived therapeutics

The Pipeline for iPSC-Derived Cell Therapeutics in 2021

My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2021 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: [email protected] | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.